Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Cholecalciferol Exhibits no Antibacterial Effect on Staphylococcus aureus and Escherichia coli: An in vitro Study

Author(s): Shilia Jacob Kurian, Avirup Biswas, Shrivathsa Kulavalli, Jesil Mathew Aranjani, Amrita Pattanaik, Murali Munisamy, Kavitha Saravu, Gabriel Sunil Rodrigues and Sonal Sekhar Miraj*

Volume 19, Issue 4, 2024

Published on: 24 January, 2024

Page: [315 - 321] Pages: 7

DOI: 10.2174/0127724344277290231211051800

Price: $65

Abstract

Background: The pleiotropic effect of cholecalciferol (vitamin D3) has gained significant momentum and has been explored widely.

Objectives: The study aimed to investigate the antimicrobial effect of cholecalciferol against S. aureus and E. coli.

Methods: An in vitro study was performed for the antimicrobial effect of cholecalciferol against S. aureus and E. coli. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined following the broth microdilution method.

Results: The MIC value of cholecalciferol against both S. aureus and E. coli was 0.312 mg/ml, and the MBC for both organisms was 1.25 mg/ml. However, we also observed a significant antimicrobial effect in the dimethyl sulfoxide (DMSO) control at 12.5% (v/v). Therefore, the observed antimicrobial effect may be attributed to DMSO, indicating cholecalciferol does not directly inhibit S. aureus and E. coli.

Conclusion: This study indicates that cholecalciferol does not directly inhibit S. aureus and E. coli. Hence, we suggest exploring the antibacterial properties of other vitamin D analogs, such as calcitriol or its synergetic effect with other antimicrobial agents.

« Previous Next »
Graphical Abstract

[1]
Brown AF, Leech JM, Rogers TR, McLoughlin RM. Staphylococcus aureus colonization: Modulation of host immune response and impact on human vaccine design. Front Immunol 2014; 4: 507.
[http://dx.doi.org/10.3389/fimmu.2013.00507] [PMID: 24409186]
[2]
Loftus MJ, Young-Sharma TE, Wati S, et al. Epidemiology, antimicrobial resistance and outcomes of Staphylococcus aureus bacteraemia in a tertiary hospital in Fiji: A prospective cohort study. Lancet Reg Health West Pac 2022; 22: 100438.
[http://dx.doi.org/10.1016/j.lanwpc.2022.100438] [PMID: 35373162]
[3]
Bonten M, Johnson JR, van den Biggelaar AHJ, et al. Epidemiology of Escherichia coli bacteremia: A systematic literature review. Clin Infect Dis 2021; 72(7): 1211-9.
[http://dx.doi.org/10.1093/cid/ciaa210] [PMID: 32406495]
[4]
Nair R, Maseeh A, Vitamin D. The “sunshine” vitamin. J Pharmacol Pharmacother 2012; 3(2): 118-26.
[PMID: 22629085]
[5]
Golpour A, Bereswill S, Heimesaat MM. Antimicrobial and immune-modulatory effects of vitamin D provide promising antibiotics-independent approaches to tackle bacterial infections – lessons learnt from a literature survey. Eur J Microbiol Immunol (Bp) 2019; 9(3): 80-7.
[http://dx.doi.org/10.1556/1886.2019.00014] [PMID: 31662886]
[6]
Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022; 399(10325): 629-55.
[http://dx.doi.org/10.1016/S0140-6736(21)02724-0] [PMID: 35065702]
[7]
Chung C, Silwal P, Kim I, Modlin RL, Jo EK. Vitamin D-cathelicidin axis: At the crossroads between protective immunity and pathological inflammation during infection. Immune Netw 2020; 20(2): e12.
[http://dx.doi.org/10.4110/in.2020.20.e12] [PMID: 32395364]
[8]
Tintino SR, Morais-Tintino CD, Campina FF, et al. Action of cholecalciferol and alpha-tocopherol on Staphylococcus aureus efflux pumps. EXCLI J 2016; 15: 315-22.
[http://dx.doi.org/10.17179/excli2016-277] [PMID: 27298617]
[9]
Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Who 2017; 2017: 1-7.
[10]
Performance standards for antimicrobial susceptibility testing In: CLSI supplement M100 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute 2020.
[11]
Abd Algaffar SO, Verbon A, van de Sande WWJ, Khalid SA. Development and validation of an in vitro resazurin-based susceptibility assay against madurella mycetomatis. Antimicrob Agents Chemother 2021; 65(3): e01338-20.
[http://dx.doi.org/10.1128/AAC.01338-20] [PMID: 33318015]
[12]
O’Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267(17): 5421-6.
[http://dx.doi.org/10.1046/j.1432-1327.2000.01606.x] [PMID: 10951200]
[13]
Khelkal IN. Comparison the antibacterial activity of vitamin D2 and D3. Al-Mustansiriyah J Sci 2017; 27(4)
[http://dx.doi.org/10.23851/mjs.v27i4.16]
[14]
Almoudi MMM, Hussein AS, Abu Hassan MI, et al. The antibacterial effects of vitamin D3 against mutans streptococci: An in vitro study. Eur Oral Res 2021; 55(1): 8-15.
[http://dx.doi.org/10.26650/eor.20210119] [PMID: 33937756]
[15]
Poddighe D, Vangelista L. Staphylococcus aureus infection and persistence in chronic rhinosinusitis: Focus on leukocidin ED. Toxins 2020; 12(11): 678.
[http://dx.doi.org/10.3390/toxins12110678] [PMID: 33126405]
[16]
Liao S, Huang Y, Zhang J, et al. Vitamin D promotes epithelial tissue repair and host defense responses against influenza H1N1 virus and Staphylococcus aureus infections. Respir Res 2023; 24(1): 175.
[http://dx.doi.org/10.1186/s12931-023-02477-4] [PMID: 37407993]
[17]
Kalińczak-Górna P, Radajewski K, Burduk P. Relationship between the severity of inflammatory changes in chronic sinusitis and the level of vitamin d before and after the FESS procedure. J Clin Med 2021; 10(13): 2836.
[http://dx.doi.org/10.3390/jcm10132836] [PMID: 34198970]
[18]
Mohanty S, Kamolvit W, Hertting O, Brauner A. Vitamin D strengthens the bladder epithelial barrier by inducing tight junction proteins during E. coli urinary tract infection. Cell Tissue Res 2020; 380(3): 669-73.
[http://dx.doi.org/10.1007/s00441-019-03162-z] [PMID: 31930458]
[19]
Hertting O, Holm Å, Lüthje P, et al. Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder. PLoS One 2010; 5(12): e15580.
[http://dx.doi.org/10.1371/journal.pone.0015580] [PMID: 21179490]
[20]
Assa A, Vong L, Pinnell LJ, et al. Vitamin D deficiency predisposes to adherent-invasive Escherichia coli-induced barrier dysfunction and experimental colonic injury. Inflamm Bowel Dis 2015; 21(2): 297-306.
[http://dx.doi.org/10.1097/MIB.0000000000000282] [PMID: 25590952]
[21]
Lowry MB, Guo C, Zhang Y, et al. A mouse model for vitamin D-induced human cathelicidin antimicrobial peptide gene expression. J Steroid Biochem Mol Biol 2020; 198: 105552.
[http://dx.doi.org/10.1016/j.jsbmb.2019.105552] [PMID: 31783153]
[22]
Patria FF, Ceccarini MR, Codini M, et al. A role for neutral sphingomyelinase in wound healing induced by keratinocyte proliferation upon 1α 25-Dihydroxyvitamin D3 treatment. Int J Mol Sci 2019; 20(15): 3634.
[http://dx.doi.org/10.3390/ijms20153634] [PMID: 31349547]
[23]
Wang D, Lin L, Lei K, et al. Vitamin D3 analogue facilitates epithelial wound healing through promoting epithelial-mesenchymal transition via the Hippo pathway. J Dermatol Sci 2020; 100(2): 120-8.
[http://dx.doi.org/10.1016/j.jdermsci.2020.08.015] [PMID: 32938565]
[24]
Su Y, Ganguli-Indra G, Bhattacharya N, et al. Codelivery of 1α25-Dihydroxyvitamin D3 and CYP24A1 inhibitor VID400 by nanofiber dressings promotes endogenous antimicrobial peptide LL-37 induction. Mol Pharm 2022; 19(3): 974-84.
[http://dx.doi.org/10.1021/acs.molpharmaceut.1c00944] [PMID: 35179903]
[25]
Schauber J, Dorschner RA, Coda AB, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D–dependent mechanism. J Clin Invest 2007; 117(3): 803-11.
[http://dx.doi.org/10.1172/JCI30142] [PMID: 17290304]
[26]
Tian XQ, Chen TC, Holick MF. 1,25‐Dihydroxyvitamin D3: A novel agent for enhancing wound healing. J Cell Biochem 1995; 59(1): 53-6.
[http://dx.doi.org/10.1002/jcb.240590107] [PMID: 8530536]
[27]
Shekhar C. An innovative technique in local antibiotic delivery method in open infected wounds of the musculoskeletal system. Int J Low Extrem Wounds 2019; 18(2): 153-60.
[http://dx.doi.org/10.1177/1534734619841764] [PMID: 31066316]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy